Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L Hauser

Showing results (151-160 of 322) with videos related to

Pageof 33
Sort By:
Annals of Clinical and Translational Neurology|January 13, 2017
Onset of secondary progressive MS after long-term rituximab therapy - a case reportH-Christian von Büdingen, Antje Bischof, Erica L Eggers, et al.
Annals of Neurology|January 26, 2012
Fighting decision fatigueAdam F Stewart, Donna M Ferriero, S Andrew Josephson, et al.
Brain : a Journal of Neurology|August 31, 2010
Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosisSergio E Baranzini, Radhika Srinivasan, Pouya Khankhanian, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
Neurology. Clinical Practice|September 6, 2021
Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShareRiley Bove, Christa A Bruce, Chelsea K Lunders, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2021
Specific hypomethylation programs underpin B cell activation in early multiple sclerosisQin Ma, Stacy J Caillier, Shaun Muzic, et al.
Lancet (London, England)|November 4, 2011
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, David Li, Peter A Calabresi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Human Molecular Genetics|October 5, 2015
A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactomeAlessandro Didonna, Noriko Isobe, Stacy J Caillier, et al.
BMC Medical Genetics|July 28, 2015
Genetic contribution to multiple sclerosis risk among Ashkenazi JewsPouya Khankhanian, Takuya Matsushita, Lohith Madireddy, et al.
Pageof 33

Showing results (151-160 of 322) with videos related to

Sort By:
Pageof 33
Annals of Clinical and Translational Neurology|January 13, 2017
Onset of secondary progressive MS after long-term rituximab therapy - a case reportH-Christian von Büdingen, Antje Bischof, Erica L Eggers, et al.
Annals of Neurology|January 26, 2012
Fighting decision fatigueAdam F Stewart, Donna M Ferriero, S Andrew Josephson, et al.
Brain : a Journal of Neurology|August 31, 2010
Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosisSergio E Baranzini, Radhika Srinivasan, Pouya Khankhanian, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
Neurology. Clinical Practice|September 6, 2021
Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShareRiley Bove, Christa A Bruce, Chelsea K Lunders, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2021
Specific hypomethylation programs underpin B cell activation in early multiple sclerosisQin Ma, Stacy J Caillier, Shaun Muzic, et al.
Lancet (London, England)|November 4, 2011
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, David Li, Peter A Calabresi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Human Molecular Genetics|October 5, 2015
A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactomeAlessandro Didonna, Noriko Isobe, Stacy J Caillier, et al.
BMC Medical Genetics|July 28, 2015
Genetic contribution to multiple sclerosis risk among Ashkenazi JewsPouya Khankhanian, Takuya Matsushita, Lohith Madireddy, et al.
Pageof 33